Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization

• Status: Completed
• Trial end date: 2014-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this retrospective study was to assess the outcome of In Vitro Fertilization (IVF) according to the type of medication used for controlled ovarian stimulation (COS). The study compared the pregnancy rate obtained by 398 patients who had received COS with recombinant Follicle Stimulating Hormone (rFSH) plus recombinant Luteinising Hormone (rLH) in 2:1 ratio vs. the one observed in 450 patients who had been treated with human Menopausal Gonadotropin (hMG), stratifying results according to the number of retrieved oocytes.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Turin, Italy
• Treatments: Follicle Stimulating Hormone; Menotropins

Criteria

Inclusion Criteria:

• infertility

• need to undergo IVF

• circulating basal FSH above 6.5 UI/l

• circulating AMH 0.1-2 ng/ml

• basal antral follicle count between 3 and 15

Exclusion Criteria:

• circulating basal FSH below 6.5 UI/l

• circulating AMH below 0.1 ng/ml or above 2 ng/ml

• basal antral follicle count below 3 or above 15